Mankind Pharma Q2 profit rises 38% to Rs 716 crore

What happened: Mankind Pharma reported a 38% rise in Q2 profit to Rs 716 crore, up from Rs 520.2 crore a year earlier, according to a regulatory filing. Key numbers: Q2 PAT Rs 716 crore, up 38%. Year-ago PAT Rs 520.2 crore. Revenue Rs 4,337.9 crore versus Rs 3,697.2 crore a year ago. Why it matters: Vice chairman and managing director Rajeev Juneja attributed the performance to disciplined execution and strengthening business fundamentals, and cited the Armed Cell Therapeutics acquisition as a strategic entry into Next-Generation CAR-T therapies. Coverage: 3 outlets in 24h

Mankind Pharma reported a 38% rise in Q2 profit to Rs 716 crore, up from Rs 520.2 crore a year earlier, according to a regulatory filing.

Vice chairman and managing director Rajeev Juneja attributed the performance to disciplined execution and strengthening business fundamentals, and cited the Armed Cell Therapeutics acquisition as a strategic entry into Next-Generation CAR-T therapies.